Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1209-1218

  Rojas, Jose M ^a   Wang, Lihui ^a   Owen, Sally ^a   Knight, Katy ^a   Watmough, Sarah J ^a   Clark, Richard E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD4 ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA A3 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; L SELECTIN; TRANSCRIPTION FACTOR FOXP3; TUBERCULIN; VIRUS PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CONTROL; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE; TUMOR IMMUNITY;

ADULT; AGED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 78549290311     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.09.004     Document Type: Article

References (38)

1. Umiel T., Trainin N. Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes. Transplantation 1974, 18:244-250.
2. Gershon R.K. A disquisition on suppressor T cells. Transplant Rev 1975, 26:170-185.
3. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
4. Stephens L.A., Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol 2000, 165:3105-3110.
5. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
6. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
7. Levings M.K., Sangregorio R., Roncarolo M.G. Human CD25(+)CD4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193:1295-1302.
8. Ng W.F., Duggan P.J., Ponchel F., et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001, 98:2736-2744.
9. Stephens L.A., Mottet C., Mason D., Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001, 31:1247-1254.
10. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
11. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
12. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
13. Hinz S., Pagerols-Raluy L., Oberg H.H., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007, 67:8344-8350.
14. Yamamoto M., Tsuji-Takayama K., Suzuki M., et al. Comprehensive analysis of FOXP3 mRNA expression in leukemia and transformed cell lines. Leuk Res 2008, 32:651-658.
15. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
16. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-5218.
17. Woo E.Y., Chu C.S., Goletz T.J., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
18. Marshall N.A., Christie L.E., Munro L.R., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
19. Beyer M., Kochanek M., Darabi K., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
20. Viguier M., Lemaitre F., Verola O., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
21. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
22. Nadal E., Garin M., Kaeda J., Apperley J., Lechler R., Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007, 21:472-479.
23. Wang L., Pearson K., Pillitteri L., Ferguson J.E., Clark R.E. Serial Monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002, 118:771-777.
24. Hughes T.P., Deininger M.W., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
25. Lucas C.M., Wang L., Austin G.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
26. Rojas J.M., Knight K., Wang L., Clark R.E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21:2287-2295.
27. Liu W., Putnam A.L., Xu-Yu Z., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
28. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
29. Jung T.M., Dailey M.O. Rapid modulation of homing receptors (gp90MEL-14) induced by activators of protein kinase C. Receptor shedding due to accelerated proteolytic cleavage at the cell surface. J Immunol 1990, 144:3130-3136.
30. Clark R.E., Dodi I.A., Hill S.C., et al. Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001, 98:2887-2893.
31. Allan S.E., Crome S.Q., Crellin N.K., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
32. Appel S., Boehmler A.M., Grunebach F., et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004, 103:538-544.
33. Boissel N., Rousselot P., Raffoux E., et al. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol 2006, 79:747-756.
34. Sato N., Narita M., Takahashi M., et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003, 21:67-75.
35. Aswald J.M., Lipton J.H., Aswald S., Messner H.A. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther 2002, 7:143-149.
36. Chen J., Schmitt A., Giannopoulos K., et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 2007, 31:1133-1139.
37. Larmonier N., Janikashvili N., LaCasse C.J., et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 2008, 181:6955-6963.
38. Rohon P., Porkka K., Mustjoki S. Effect of tyrosine kinase inhibitors on regulatory T-cells (TREGS) in patients with chronic myeloid leukaemia (CML). Haematologica 2008, 93(suppl 1):44-45. [abstract].